CapsoVision (NASDAQ:CV) Stock Price Up 51% – Here’s Why

CapsoVision, Inc. (NASDAQ:CV)’s stock price rose 51% during mid-day trading on Tuesday . The stock traded as high as $10.99 and last traded at $10.99. Approximately 147,901 shares were traded during trading, an increase of 32% from the average daily volume of 111,696 shares. The stock had previously closed at $7.28.

Analyst Ratings Changes

Several brokerages have commented on CV. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. Zacks Research raised CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research report on Monday. Finally, Roth Capital set a $7.00 price target on shares of CapsoVision in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.00.

CapsoVision Trading Up 22.2%

The business’s fifty day simple moving average is $5.55.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CapsoVision stock. Citadel Advisors LLC bought a new stake in shares of CapsoVision, Inc. (NASDAQ:CV) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned approximately 0.05% of CapsoVision at the end of the most recent quarter.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.